Appointments
Avectas announces Dr Justin McCue as Chief Technology Officer
Avectas, a cell engineering technology business, has announced the appointment of Dr Justin McCue, as its new Chief Technology Officer.
Dr McCue will be based in Boston and will lead the overall technological and scientific strategy for Avectas as it commercialises its SOLUPORE platform with therapeutic developers.
Demand for novel cell transfection technologies to enable next-generation cell therapies is growing.
The SOLUPORE technology offers a new transfection option for therapeutic developers which is “differentiated by the quality of the modified cells, which retain high viability and functionality and proliferate rapidly,” the company said.
Dr. McCue said:
“I am thrilled to join the Avectas team as Chief Technology Officer.
“Avectas is uniquely positioned with its innovative SOLUPORE technology to transform how therapeutic developers engineer and manufacture their next-generation gene-modified cell therapy products.
“I look forward to further driving innovation for the company while continuing its focus on deploying and commercialising the SOLUPORE technology.”
Michael Maguire, PhD, CEO of Avectas, said:
“I am delighted to welcome Justin to the team.
“Justin’s deep experience in the cell and gene therapy industry will strengthen our team as we introduce our SOLUPORE platform.
“I am excited about the technical and scientific possibilities that a scientific leader of Justin’s calibre will bring.”
Most recently, Dr McCue was Vice President of Technical Operations at Repertoire Immune Medicines where he led CMC development and clinical manufacturing of their multi-targeted antigen-specific T-cell platform.
Before this, Dr. McCue spent more than 15 years in the cell therapy and biopharma industry, including roles at Juno/Celgene and Biogen.
Dr. McCue has been involved in developing and commercialising biologics and cell therapy modalities in technical development, manufacturing, supply chain, quality and programme management.
Dr McCue holds a bachelor’s degree from the University of California in Berkeley and a PhD from M.I.T. in Chemical Engineering.
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
